rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ADIL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
      Oct 28Yahoo FinanceADIL
      Adial Pharmaceuticals names Celia Economides as CFO
      Oct 26Investing.comADIL
      Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
      Oct 26Yahoo FinanceADIL
      Adial Pharmaceuticals appoints David Rubenstein as chief scientist
      Oct 16Investing.comADIL
      Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

      Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027 GLEN ALLEN, Va., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) ("Adial" or the "Company"), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D.

      Oct 16Yahoo FinanceADIL
      Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision

      Detailed price information for Adial Pharmaceuticals Inc (ADIL-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailADIL
      Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $4.22 per share, the closing price of the Company’s common stock on September 25, 2026, the effective date of grant and has a

      Sep 30Yahoo FinanceADIL
      Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-

      Aug 25Yahoo FinanceADIL

      This is the newest page. Registered accounts read further back.